Adhesion of platelets to immobilized fibrinogen appears to play an important role in a variety of physiologic and pathologic phenomena. We previously observed that the fibrinogen concentration used to coat polystyrene wells affected the morphology and distribution of GP IIb/ IIIa receptors on the surface of platelets adherent to the fibrinogen. One possible explanation for these differences is that fibrinogen immobilized at high density adopts a different conformation than fibrinogen immobilized at low density. To address this possibility, we studied the binding of a panel of anti-fibrinogen monoclonal antibodies (mAbs) to fibrinogen immobilized at different coating densities. Three different patterns of binding were observed: 1) a linear increase in binding to wells coated with 1-10 μg/ml fibrinogen, followed by a lesser increase or plateau at higher fibrinogen concentrations (mAbs Fd4-4E1, Fd4-7B3, 1D4, 4-2); 2) minimal reactivity at all fibrinogen concentrations (mAbs GC4-1A12, 2C34); 3) a biphasic response, with a linear increase up to 10 μg/ml fibrinogen and then a significant decline in binding at higher fibrinogen concentrations (mAbs 311, 31A9, FPA 19/7, 9C3, 1C5-A5/2, 44-3). The patterns of mAb binding to fibrinogen immobilized from plasma were similar. Most mAbs that demonstrated a biphasic response bound poorly or not at all to soluble fibrinogen, while mAbs that demonstrated a linear/plateau response were able to bind soluble fibrinogen. At equal surface densities, mAbs that bound biphasically, particularly mAb 1C5-A5/2, were more reactive to urea-denatured than native fibrinogen. mAbs 1C5-A5/2 and 44-3 are specific for γ 1-78 and 95-265, respectively, suggesting that the fibrinogen γ-chain may be sensitive to changes in conformation induced by immobilization. In summary, these data suggest that fibrinogen immobilized at 1-10 μg/ml adopts a conformation unlike soluble fibrinogen, while fibrinogen immobilized at >30 μg/ml adopts a more solution-like conformation. These differences in fibrinogen conformation may partially account for the ability of platelets to bind to immobilized fibrinogen without the addition of agonist, as well as the differences in spreading and GPIIb/IIIa distribution on platelets adherent to high- versus low-density immobilized fibrinogen.
References
1
Lassila R,
Peltonen S,
Lepantalo M,
Saarinen O,
Kauhanen P,
Manninen V.
Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-42.
5
Hatton MWCS,
Moar SL,
Richardson M.
Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface: correlation of uptake of fibrinogen and antithrombin with thrombin generation by the exposed subendothelium. Am J Pathol 1989; 135: 499-508.
7
Ziats NP,
Pankowsky DA,
Tierney BP,
Ratnoff OD,
Anderson JM.
Adsorption of Hageman factor and other human plasma proteins to biomedical polymers. J Lab Clin Med 1990; 116: 687-96.
9
Nagai H,
Handa M,
Kawai Y,
Watanabe K,
Ikeda Y.
Evidence that plasma fibrinogen and platelet membrane GPIIb-IIIa are involved in the adhesion of platelets to an artificial surface exposed to plasma. Thromb Res 1993; 71: 467-77.
10
Batllu AL,
Laurent A,
Lu H,
Elalami I,
Jacob P,
Mundler O,
Merland JJ,
Lautier A,
Soria J,
Soria C.
Fibrinogen binding and platelet retention: relationship with the thrombogenicity of catheters. J Biomed Mater Res 1996; 30: 101-8.
12
Park K,
Mosher DF,
Cooper SL.
Acute surface-induced thrombosis in the canine ex vivo model: Importance of protein composition of the initial platelet monolayer and platelet activation. J Biomed Mater Res 1986; 20: 589-612.
13
Coller BS,
Kutok JL,
Scudder LE,
Galanakis DK,
West SM,
Rudomen GS,
Springer KT.
Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. J Clin Invest 1993; 92: 2796-806.
15
Savage BJ,
Ruggeri ZM.
Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on non-activated platelets. J Biol Chem 1991; 266: 11227-33.
16
Kieffer N,
Fitzgerald LA,
Wolf D,
Cheresh DA,
Phillips DR.
Adhesive properties of the β3 integrins: comparison of GPIIb-IIIa and the vitronectin receptor expressed in human melanoma cells. J Cell Biol 1991; 113: 451-61.
20
Coller BS,
Springer KT,
Beer JH,
Mohandas N,
Scudder LE,
Norton KJ,
West SM.
Thromboerythrocytes: in vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 1992; 89: 546-55.
23
Coller BS,
Peerschke EI,
Scudder LE,
Sullivan CA.
A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
27
Bini A,
Mesa-Tejada R,
Fenoglio JJ,
Kudryk B,
Kaplan KL.
Immunohisto-chemical characterization of fibrin(ogen)-related antigen in human tissues using monoclonal antibodies. Lab Invest 1989; 60: 814-21.
30
Cierniewski CS,
Kloczewiak M,
Budzynski AZ.
Expression of primary polymerization sites in the D domain of human fibrinogen depends on intact conformation. J Biol Chem 1986; 261: 9116-21.
31
Chinn JA,
Posso SE,
Horbett TA,
Ratner BD.
Postadsorptive transitions in fibrinogen adsorbed to biomer: changes in baboon platelet adhesion, antibody binding, and sodium dodecyl sulfate elutability. J Biomed Mater Res 1991; 25: 535-55.
34
Retzinger GS,
Cook BC,
Deanglis AP.
The binding of fibrinogen to surfaces and the identification of two distinct surface-bound species of the protein. J Colloid Interface Sci 1994; 168: 514-21.
38
Moskowitz KA,
Boeger C,
Scudder LE,
Patel D,
Vaananen H,
Eisinger J,
Coller BS.
Platelets spread differently on low density versus high density fibrinogen as judged by their shape change and ability to bind soluble fibrinogen. Blood 1996; 88: 34a.
39
Schielen WJG,
Voskuilen M,
Tesser GI,
Niewenhuizen W.
The sequence Aα-(148-160) in fibrin, but not fibrinogen, is accessible to monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86: 8951-4.
43
Abrams CS,
Ellison N,
Budzynski AZ,
Shattil SJ.
Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-38.
44
Zamarron C,
Ginsberg MH,
Plow EF.
A receptor-induced binding site in fibrinogen elicited by its interaction with platelet membrane glycoprotein IIb-IIIa. J Biol Chem 1991; 266: 16193-9.
47
Veklich YI,
Gorkun OV,
Medved LV,
Nieuwenhuizen W,
Weisel JW.
Carboxy-terminal portions of the α chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated αC fragments on polymerization. J Biol Chem 1993; 268: 13577-85.
53
Lyman B,
Rosenberg L,
Karpatkin S.
Biochemical and biophysical aspects of human platelet adhesion to collagen fibers. J Clin Invest 1971; 50: 1854-63.
54
Coller BS,
Beer JH,
Scudder LE.
Adsorption of plasma glycoproteins to collagen converts platelet adhesion from being mediated by GPIa/IIa to being mediated by GPIa/IIa and/or GPIIb/IIIa. Blood 1988; 72: 318a.
55
Packham MA,
Evans G,
Glynn MF,
Mustard JF.
The effect of plasma proteins on the interaction of platelets with glass surfaces. J Lab Clin Med 1969; 73: 686-97.
58
Brash JL,
Uniyal S.
Dependence of albumin-fibrinogen simple and competitive adsorption on surface properties of biomaterials. J Polymer Sci 1979; C66: 377.
